Cost‐effectiveness analysis of leadless cardiac resynchronization therapy

Abstract

AbstractBackgroundThe Wireless Stimulation Endocardially for CRT (WiSE‐CRT) system is a novel technology used to treat patients with dyssynchronous heart failure (HF) by providing leadless cardiac resynchronization therapy (CRT). Observational studies have demonstrated its safety and efficacy profile, however, the treatment cost‐effectiveness has not previously been examined.MethodsA cost‐effectiveness evaluation of the WiSE‐CRT System was performed using a cohort‐based economic model adopting a “proportion in state” structure. In addition to the primary analysis, scenario analyses and sensitivity analyses were performed to test for uncertainty in input parameters. Outcomes were quantified in terms of quality‐adjusted life year (QALY) differences.ResultsThe primary analysis demonstrated that treatment with the WiSE‐CRT system is likely to be cost‐effective over a lifetime horizon at a QALY reimbursement threshold of £20 000, with a net monetary benefit (NMB) of £3781 per QALY. Cost‐effectiveness declines at time horizons shorter than 10 years. Sensitivity analyses demonstrated that average system battery life had the largest impact on potential cost‐effectiveness.ConclusionWithin the model limitations, these findings support the use of WiSE‐CRT in indicated patients from an economic standpoint. However, improving battery technology should be prioritized to maximize cost‐effectiveness in times when health services are under significant financial pressures.